IDH1 and central nervous system cancer: In summary, our study, drawing from clinical data of over 2500 glioma patients, confirms the superior prognosis of IDH1-mutant glioma patients compared to those with IDH1 wild type, coupled with their heightened sensitivity to TMZ.